The statement addresses potential concerns regarding tariff effects on the global supply of company products and services

WAYNE, PENNSYLVANIA - April 28, 2025 (NEWMEDIAWIRE) - Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047) specializing in biological research reagents and related technical contract research services, has issued the following statement in reference to global trade discussions and the potential impact tariffs may have on the supply of company products and services:

Dear Colleagues, Partners, Clients and Shareholders:

In light of the ongoing trade discussions among the major economies, we here at Sino Biological want to take a moment to reaffirm our full commitment to uninterrupted service and supply.

While Sino Biological maintains substantial operations in China, we have proactively invested in a robust North American infrastructure. These efforts have ensured business continuity without the need for broad price adjustments.

Key actions we’ve taken include:

• Launched the Center for Bioprocessing (C4B) in Houston, Texas in Nov 2023, which produces catalog products and delivers CRO services;
• Acquired SignalChem Biotech (SCB) in Vancouver, Canada, in May 2024, expanding our local manufacturing and service capacity;
• Stocked over 90% of our catalog inventory at our Wayne, Pennsylvania warehouse to support long-term supply assurance.

These measures have positioned us to continue meeting your product and service needs without disruption. We encourage you to explore using our C4B (Houston, U.S.) and SCB (Vancouver, Canada) production sites for strategic sourcing and CRO partnerships.

Thank you for your continued trust. We look forward to supporting your research with the same quality and consistency you’ve come to expect from Sino Biological.

Regards,

Rob Burgess 

Chief Business Officer

Sino Biological, Inc.

About Sino Biological

Sino Biological is an international reagent supplier and contract research service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced with a stringent quality management system, and include unique bioreagents addressing areas such as cell therapy, stem cell, and infectious disease research.  In addition, Sino Biological offers contract research production services for the custom development of full length, bioactive proteins and high-affinity antibodies, along with other services. To learn more about Sino Biological visit www.sinobiological.com, follow the company on LinkedIn or @SinoInc on Twitter.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on Sino Biological management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Sino Biological has no control. Sino Biological assumes no obligation to update these forward-looking statements and does not intend to do so.

For media inquiries or partnership opportunities, please contact: 

Sino Biological, Inc.
gmo@sinobiological.cn
www.sinobiological.com 

View the original release on www.newmediawire.com

This press release is distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Sino Biological Issues Formal Statement Regarding Current Global Tariff Discussions.